{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphomas&page=20",
    "query": {
      "condition": "Lymphomas",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 5753,
    "total_pages": 576,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphomas&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphomas&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T18:19:12.222Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01780662",
      "title": "Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Childhood Hodgkin Lymphoma",
        "Refractory Childhood Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "13 Months to 30 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-01-31",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 109,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Downey, California + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01780662"
    },
    {
      "nct_id": "NCT00755040",
      "title": "Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "cyclosporine ophthalmic emulsion",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2008-10",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00755040"
    },
    {
      "nct_id": "NCT06263491",
      "title": "Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-05-29",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06263491"
    },
    {
      "nct_id": "NCT03970096",
      "title": "Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic CD34+-enriched and CD45RA-depleted PBSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "1 Year to 60 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-11-19",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970096"
    },
    {
      "nct_id": "NCT02181218",
      "title": "Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphoma, T-Cell, Peripheral",
        "Hodgkin Disease",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-02-04",
      "completion_date": "2020-06-26",
      "has_results": false,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • St Louis, Missouri",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02181218"
    },
    {
      "nct_id": "NCT00109824",
      "title": "Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "valproic acid",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109824"
    },
    {
      "nct_id": "NCT00033423",
      "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "yttrium Y 90 ibritumomab tiuxetan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2001-08",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2013-12-13",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Stanford, California • Rochester, Minnesota",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033423"
    },
    {
      "nct_id": "NCT07565220",
      "title": "Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia (ALL)",
        "Acute Myeloid Leukemia (AML)",
        "Acute Leukemia",
        "Myelodysplastic Syndrome(MDS)",
        "Myeloproliferative Neoplasm (MPN)"
      ],
      "interventions": [
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "PBSC infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sawa Ito, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-07-27",
      "completion_date": "2030-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07565220"
    },
    {
      "nct_id": "NCT04315324",
      "title": "Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Refractory T Lymphoblastic Lymphoma",
        "T Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "AKR1C3-activated Prodrug AST-3424",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2021-02-08",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 163,
      "location_summary": "Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04315324"
    },
    {
      "nct_id": "NCT01207076",
      "title": "AHN-12 Biodistribution in Advanced Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "90Y-AHN-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2013-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-23T18:19:12.222Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01207076"
    }
  ]
}